Osmetech gained exclusive access to Marshfield Clinic’s warfarin biomarker. The company says that it will develop, manufacture, and sell a genetic test based on the clinic’s research.
Osmetech plans to market this product in the first half of 2008, according to James White, CEO, Osmetech. He adds that it will more accurately determine the initial level of warfarin a patient should be prescribed.
“We look forward to the day when our patients realize improved anticoagulation outcomes from incorporating our warfarin SNP marker into Osmetech’s XT-8 platform,” remarks Karl Ulrich, M.D., president and CEO, Marshfield Clinic. “This is a key first step in bringing our new genetic marker into the marketplace for widespread use.”